Scientific Committee

Dr David Collingridge is the Editor-in-Chief of The Lancet Oncology and Vice President of editorial strategy and innovation for The Lancet’s large portfolio of clinical journals. Prior to his appointments at The Lancet, he gained a PhD in tumour biology from the Gray Cancer Institute/University College London, UK, and held research positions in the Department of Therapeutic Radiology, Yale University, CT, USA, and in the PET Oncology Group, Imperial College School of Medicine, London, UK. Dr Collingridge has won awards for projects focused on cancer control in low-to-middle income countries; has published numerous peer-review articles, editorials, opinion pieces, and news reports; has co-authored a textbook on radiobiology and has been a contributor to various other books; and lectures on the publishing industry, how to write a successful manuscript, health activism, and clinical trial design. Finally, he was previously a Clinical Associate Professor of Radiation Medicine at Hofstra/Northwell Health, Lake Success, NY, USA, and is currently a Visiting Professor of Global Oncology at King’s College London, UK.